- Home
- DTCK vs CMMB Comparison
DTCK vs CMMB Comparison
Compare DTCK & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTCK
- CMMB
- Stock Information
- Founded
- DTCK 1999
- CMMB 2004
- Country
- DTCK Singapore
- CMMB Israel
- Employees
- DTCK N/A
- CMMB N/A
- Industry
- DTCK Farming/Seeds/Milling
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- DTCK Industrials
- CMMB Health Care
- Exchange
- DTCK Nasdaq
- CMMB Nasdaq
- Market Cap
- DTCK 22.8M
- CMMB 22.0M
- IPO Year
- DTCK 2023
- CMMB N/A
- Fundamental
- Price
- DTCK $0.90
- CMMB $3.03
- Analyst Decision
- DTCK
- CMMB Strong Buy
- Analyst Count
- DTCK 0
- CMMB 2
- Target Price
- DTCK N/A
- CMMB $26.50
- AVG Volume (30 Days)
- DTCK 130.9K
- CMMB 142.4K
- Earning Date
- DTCK 11-12-2025
- CMMB 11-13-2025
- Dividend Yield
- DTCK N/A
- CMMB N/A
- EPS Growth
- DTCK N/A
- CMMB N/A
- EPS
- DTCK N/A
- CMMB N/A
- Revenue
- DTCK $132,369,000.00
- CMMB N/A
- Revenue This Year
- DTCK N/A
- CMMB N/A
- Revenue Next Year
- DTCK N/A
- CMMB N/A
- P/E Ratio
- DTCK N/A
- CMMB N/A
- Revenue Growth
- DTCK N/A
- CMMB N/A
- 52 Week Low
- DTCK $0.40
- CMMB $2.96
- 52 Week High
- DTCK $1.50
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- DTCK 56.15
- CMMB 26.72
- Support Level
- DTCK $0.86
- CMMB $2.96
- Resistance Level
- DTCK $0.94
- CMMB $3.14
- Average True Range (ATR)
- DTCK 0.07
- CMMB 0.22
- MACD
- DTCK 0.01
- CMMB 0.01
- Stochastic Oscillator
- DTCK 61.18
- CMMB 8.09
About DTCK Davis Commodities Limited
Davis Commodities Ltd is an agricultural commodity trading company based in Singapore, which specializes in the trading of three main categories of agricultural commodities, namely sugar, rice, and oil and fat products. It distributes agricultural commodities to various markets, including Asia, Africa, and the Middle East. The company also provides customers of commodity offerings with complementary, ancillary services such as warehouse handling and storage, and logistics services. The Company operates across four main segments: the sale of sugar, rice, oil, and fat products, and others. Among these, the sale of sugar stands out as the primary revenue generator, contributing significantly to the company's overall income.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.